Business Model Breakdown
How Exelixis Inc Makes Money
EXEL
Market Cap
$12.6B
Annual Revenue
$2.3B
Profit Margin
35.1%
Employees
1,147
The Short Version
Exelixis is a biopharmaceutical company focused on discovering, developing, and commercializing innovative small molecule therapeutics for challenging cancers. Its primary revenue stream comes from its flagship drug, Cabometyx (cabozantinib), which is approved for various forms of kidney, liver, and thyroid cancer. The company invests heavily in research and development to expand the indications for its existing drugs and bring new compounds, like zanzalintinib, through clinical trials and regulatory approval, aiming to create a diversified portfolio of oncology treatments.
Where the Revenue Comes From
Net product revenues from Cabometyx sales (~90% of total revenue)
Collaboration revenues (from partnerships for drug development/commercialization, typically smaller contribution)
Who buys: Oncology specialists, hospitals, and healthcare systems who prescribe and administer cancer treatments to patients.
Why It Works (Competitive Advantages)
- ✔Strong intellectual property and patent protection for Cabometyx and pipeline assets like zanzalintinib.
- ✔Deep expertise and established presence in the competitive oncology therapeutic area.
- ✔Robust cash position for R&D and potential M&A to expand pipeline.
Economic Moat: Narrow (Intangible Assets/IP (strong patent protection for Cabometyx and zanzalintinib), Switching Costs (for patients on an established treatment regimen, though less potent in oncology due to disease progression))
What Our Analysis Says
DVR Score as of May 22, 2026
Exelixis continues to demonstrate robust financial performance, driven by its flagship oncology drug, Cabometyx, which showed an 8.1% YoY increase in net product revenues. The company's Q1 2026 results exceeded EPS consensus and delivered strong YoY net income growth of 31.9%. A significant catalyst is the FDA's acceptance of the NDA for zanzalintinib (XL092) in metastatic colorectal cancer, with a PDUFA date of 2026-12-03, providing a clear pathway for future growth beyond Cabometyx. The company's strong cash position of $1.43B and substantial share repurchases ($430.4M in Q1) reflect excellent capital allocation and financial health. However, despite these positives and an advancing pipeline, achieving a 10x growth target from its current $12.48B market cap within 3-5 years remains an extraordinary challenge, requiring multiple blockbuster successes and significant market penetration beyond current expectations. The company is well-managed and growing, but its established nature suggests more stable, substantial growth rather than explosive, disruptive acceleration. The score of 9 reflects this improved pipeline clarity and sustained strong fundamentals, slightly elevating it from the previous assessment due to concrete progress with zanzalintinib, while acknowledging the extreme difficulty of the 10x target.